5:47 PM
 | 
Jun 04, 2012
 |  BC Extra  |  Clinical News

Bristol-Myers reports data for anti-PD-L1 mAb

Bristol-Myers Squibb Co. (NYSE:BMY) reported data from 160 evaluable patients with advanced solid tumors in the Phase I MDX1105-01 trial of BMS-936559, a human mAb against programmed cell death 1 ligand 1 ( CD274 molecule; PD-L1;

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >